Houston, TX., — Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview by Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, at the LifeSci Summer Symposium held virtually on July 21, 2021.
LifeSci Summer Symposium
Location:
